๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

ROBUST BAYESIAN APPROACHES FOR CLINICAL TRIAL MONITORING

โœ Scribed by BRADLEY P. CARLIN; DANIEL J. SARGENT


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
899 KB
Volume
15
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

โœฆ Synopsis


The interim monitoring and final analysis of data arising from a clinical trial require an inferential method capable of convincing a broad group of potential consumers: doctors; patients; politicians; members of the media, and so on. While Bayesian methods offer a powerful and flexible analytic framework in this setting, this need to convince a diverse community necessitates a practical approach for studying and communicating the robustness of conclusions to the prior specification. In this paper we attempt to characterize the class of priors leading to a given decision (such as stopping the trial and rejecting the null hypothesis) conditional on the observed data. We evaluate the practicality and effectiveness of this procedure over a range of smoothness conditions on the prior class. First, we consider a non-parametric class of priors restricted only in that its elements must have certain prespecified quantiles. We then obtain more precise results by further restricting the prior class, first to a non-parametric class whose members are quasi-unimodal, then to a semi-parametric normal mixture class, and finally to the fully parametric normal family. We illustrate all of our comparisons with a dataset from an AIDS clinical trial that compared the effectiveness of the drug pyrimethamine and a placebo in preventing toxoplasmic encephalitis.


๐Ÿ“œ SIMILAR VOLUMES


TUTORIAL IN BIOSTATISTICS: BAYESIAN DATA
โœ PETER M. FAYERS; DEBORAH ASHBY; MAHESH K. B. PARMAR ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 293 KB ๐Ÿ‘ 2 views

Many clinical trials organizations use regular interim analyses to monitor the accruing results in large clinical trials. In disease areas such as cancer, where survival is usually a major outcome variable, ethical considerations may lead to a stipulated requirement for data monitoring of mortality.

Some extensions and applications of a Ba
โœ Peter F. Thall; Hsi-Guang Sung ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB ๐Ÿ‘ 2 views

We present some practical extensions and applications of a strategy proposed by Thall, Simon and Estey for designing and monitoring single-arm clinical trials with multiple outcomes. We show by application how the strategy may be applied to construct designs for phase IIA activity trials and phase I

Design of clinical trials for recurrent
โœ Shigeyuki Matsui; Hideaki Miyagishi ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

This paper presents a design for randomized clinical trials in which incomplete data are collected on the occurrence of potentially recurrent events through periodic monitoring. In particular, events are assumed to arise according to a point process, but information is available at the times of moni